Karyopharm Therapeutics Submits sNDA for XPOVIO in Myelofibrosis

Karyopharm Therapeutics Inc. has submitted a supplemental New Drug Application (sNDA) to the FDA for XPOVIO® (selinexor). The company seeks Accelerated Approval for the drug in combination with ruxolitinib for patients with myelofibrosis and has requested Priority Review. This submission is a key regulatory step that could expand treatment options for patients with this bone marrow cancer.